An Open Label Study to Evaluate the Effect of First Line Treatment With Tarceva in Combination With Gemcitabine on Overall Survival and Disease Progression in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall survival; time to progression
6 months
No
Clinical Trials
Study Director
Hoffmann-La Roche
Mexico: Comision Federal para la Proteccion Contra Riesgos Santarios
ML21285
NCT00642733
May 2010
Name | Location |
---|